Company / Cash & Equivalents
Apyx Medical Corp Cash & Equivalents History
FY2016-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Cash & Equivalents
$31.7M
FY2025
5-year range
$10.2M / $43.7M
FY2021-FY2025
Trend
-0.0%
vs FY2024
Sector context
Sector data unavailable
Latest sector comparison
What the data says
Cash & Equivalents has fluctuated over the past 10 years, ranging from $6M in FY2016 to $44M in FY2023.
Based on SEC 10-K filings.
$32M in FY2025 with a 5-year CAGR of -5.4%.
Declined from $44M to $32M over the past 2 years.
Cash & Equivalents over time
Growth rates
- 3-Year CAGR
- +46.0%
- 5-Year CAGR
- -5.4%
- 10-Year CAGR
- -
Key checks
Key Insights
- 5-year CAGR of -5.4%, indicating a declining trend.
- In FY2025, cash & equivalents decreased 0.0% year-over-year.
- Peak cash & equivalents was recorded in FY2023.
- Lowest cash & equivalents in the period was in FY2016.
Company context
Key Data Points
- Altman Z-Score -0.02 (distress zone, below 1.8 threshold)
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | Cash & EquivalentsValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | $31.7M | -0.0% |
| FY2024 | $31.7M | -27.3% |
| FY2023 | $43.7M | +328.3% |
| FY2022 | $10.2M | -67.0% |
| FY2021 | $30.9M | -26.4% |
| FY2020 | $41.9M | +3.1% |
| FY2019 | $40.7M | +308.7% |
| FY2018 | $9.9M | +0.0% |
| FY2017 | $9.9M | +73.5% |
| FY2016 | $5.7M | -27.7% |
As of FY2025 · SEC 10-K · Updated Jun 24, 2026